TAC1 and glioblastoma: A new, alternative option for patients with recurrent glioblastoma is the targeted alpha therapy (TAT), in the form of a local administration of substance P (neurokinin type 1 receptor ligand, NK-1) labelled with isotopes that undergo alpha decay, 213Bi or 225Ac [3].